Skip to main content
Erschienen in: Pathology & Oncology Research 3/2010

01.09.2010

Per2 Inhibits K562 Leukemia Cell Growth In Vitro and In Vivo Through Cell Cycle Arrest and Apoptosis Induction

verfasst von: Cheng-ming Sun, Shi-feng Huang, Jian-ming Zeng, Din-bing Liu, Qing Xiao, Wen-jun Tian, Xi-dan Zhu, Zong-gan Huang, Wen-li Feng

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Per2 regulates other molecular and biochemical processes beyond their established role in the regulation of the mammalian circadian clock, herein we investigated the growth inhibiting potential of Per2 in human K562 leukemia cells and the underlying mechanisms .The results showed that over-expression of Per2 induced not only cell cycle arrest at G2/M phase but also an increase in apoptosis, which was confirmed by characteristic morphological changes, FCM and evident DNA fragmentation. Further experiments confirmed both up-regulation of P53 and down-regulation of CylinB1and C-myc. On the other hand, while P53 was found to be down-regulated. CylinB1 and C-myc were up-regulated. after Per2 knockdown. In leukemia mice, Per2 transfection was shown to suppress cellular proliferation and accelerate apoptosis of K562 cells. Moreover, fewer leukemia cells were found to have infiltrated into the livers and spleens of the mice from the Per2 transfected group as compared with those from the control group. In summary, Per2 displayed a significant anti-tumor effect through cell cycle arrest and apoptosis induction in K562 cells. These data further support the emerging role of the circadian clock in critical aspects of cancer development and thorough research is underway on the mechanism of Per2 in the leukemia.
Literatur
1.
Zurück zum Zitat Reppert SM, Weaver DR (2002) Coordination of circadian timing in mammals. Nature 418:935–941CrossRefPubMed Reppert SM, Weaver DR (2002) Coordination of circadian timing in mammals. Nature 418:935–941CrossRefPubMed
2.
3.
Zurück zum Zitat Lowrey PL, Takahashi JS (2004) Mammalian circadian biology: Elucidating genome-wide levels of temporal organization. Ann Rev Genomics Hum Genet. 5:407–441CrossRef Lowrey PL, Takahashi JS (2004) Mammalian circadian biology: Elucidating genome-wide levels of temporal organization. Ann Rev Genomics Hum Genet. 5:407–441CrossRef
4.
Zurück zum Zitat Ko CH, Takahashi JS (2006) Molecular components of the mammalian circadian clock. Hum Mol Genet 15:271–277CrossRef Ko CH, Takahashi JS (2006) Molecular components of the mammalian circadian clock. Hum Mol Genet 15:271–277CrossRef
5.
Zurück zum Zitat Zheng B, Larkin DW, Albrecht U et al (1999) The mPer2 gene encodes a functional component of the mammalian circadian clock. Nature 400:169–173CrossRefPubMed Zheng B, Larkin DW, Albrecht U et al (1999) The mPer2 gene encodes a functional component of the mammalian circadian clock. Nature 400:169–173CrossRefPubMed
6.
Zurück zum Zitat Zheng B, Albrecht U, Kaasik K et al (2001) Nonredundant roles of the mPer1 and mPer2 genes in the mammalian circadian clock. Cell 105:683–694CrossRefPubMed Zheng B, Albrecht U, Kaasik K et al (2001) Nonredundant roles of the mPer1 and mPer2 genes in the mammalian circadian clock. Cell 105:683–694CrossRefPubMed
7.
Zurück zum Zitat Fu L, Lee CC (2003) The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 3:350–361CrossRefPubMed Fu L, Lee CC (2003) The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 3:350–361CrossRefPubMed
8.
Zurück zum Zitat Canaple L, Kakizawa T, Laudet V (2003) The days and nights of cancer cells. Cancer Res 63:7545–7552PubMed Canaple L, Kakizawa T, Laudet V (2003) The days and nights of cancer cells. Cancer Res 63:7545–7552PubMed
9.
Zurück zum Zitat Chen ST, Choo KB (2005) HouM.F., Yeh K.T., Kuo S.J. and Chang J.G, Deregulated expression of the PER1; PER2 and PER3 genes in breast cancers. Carcinogenesis. 26:1241–1246CrossRefPubMed Chen ST, Choo KB (2005) HouM.F., Yeh K.T., Kuo S.J. and Chang J.G, Deregulated expression of the PER1; PER2 and PER3 genes in breast cancers. Carcinogenesis. 26:1241–1246CrossRefPubMed
10.
Zurück zum Zitat Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK (2005) and Koeffler H.P, Transcription profiling of C/EBP targetsidentifies Per2 as a gene implicated in myeloid leukemia. Blood. 106:2827–2836CrossRefPubMed Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK (2005) and Koeffler H.P, Transcription profiling of C/EBP targetsidentifies Per2 as a gene implicated in myeloid leukemia. Blood. 106:2827–2836CrossRefPubMed
11.
Zurück zum Zitat Gery S, Virk RK, Chumakov K, Yu A (2007) and Koeffler H.P, The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene. 26:7916–7920CrossRefPubMed Gery S, Virk RK, Chumakov K, Yu A (2007) and Koeffler H.P, The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene. 26:7916–7920CrossRefPubMed
12.
Zurück zum Zitat Hua H, Wang Z, Halberg F et al (2006) Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci. 97:589–596CrossRefPubMed Hua H, Wang Z, Halberg F et al (2006) Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci. 97:589–596CrossRefPubMed
13.
Zurück zum Zitat MingYu Yang, Yi-Chang Liu, Sheng-Fung Lin et al (2006) Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer Sci 97:1298–1307CrossRef MingYu Yang, Yi-Chang Liu, Sheng-Fung Lin et al (2006) Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer Sci 97:1298–1307CrossRef
14.
Zurück zum Zitat Lévi F, Filipski E, Iurisci I, Li XM, Innominato P (2007) Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics. Cold Spring Harb Symp Quant Biol 72:465–475CrossRefPubMed Lévi F, Filipski E, Iurisci I, Li XM, Innominato P (2007) Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics. Cold Spring Harb Symp Quant Biol 72:465–475CrossRefPubMed
15.
Zurück zum Zitat Fu L, Pelicano H, Liu J, Lee C (2002) The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111:41–50CrossRefPubMed Fu L, Pelicano H, Liu J, Lee C (2002) The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111:41–50CrossRefPubMed
16.
Zurück zum Zitat Elledge SJ (1996) Cell cycle checkpoints: preventing an identity crisis. Science 274:1664–1672CrossRefPubMed Elledge SJ (1996) Cell cycle checkpoints: preventing an identity crisis. Science 274:1664–1672CrossRefPubMed
17.
Zurück zum Zitat Shah JV, Cleveland DW (2000) Waiting for anaphase: Mad2 and the spindle assembly checkpoint. Cell 103:997–1000CrossRefPubMed Shah JV, Cleveland DW (2000) Waiting for anaphase: Mad2 and the spindle assembly checkpoint. Cell 103:997–1000CrossRefPubMed
18.
Zurück zum Zitat Fluge O, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE (2006) Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid. 16:161–175CrossRefPubMed Fluge O, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE (2006) Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid. 16:161–175CrossRefPubMed
19.
Zurück zum Zitat Hansel DE, Dhara S, Huang RC (2005) CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target. Am J Surg Pathol 29:390–399CrossRefPubMed Hansel DE, Dhara S, Huang RC (2005) CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target. Am J Surg Pathol 29:390–399CrossRefPubMed
20.
Zurück zum Zitat Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M, Matsuura N (2000) Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology 59:68–74CrossRefPubMed Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M, Matsuura N (2000) Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology 59:68–74CrossRefPubMed
21.
Zurück zum Zitat Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F (2003) and Okamura, H, Control mechanism of the circadian clock for timing of cell division in vivo. Science 302:255–259CrossRefPubMed Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F (2003) and Okamura, H, Control mechanism of the circadian clock for timing of cell division in vivo. Science 302:255–259CrossRefPubMed
22.
Zurück zum Zitat Granda TG, Liu XH, Smaaland R, Cermakian N, Filipski E, Sassone-Corsi P, Lévi F (2005) Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. FASEB J 19:304–306PubMed Granda TG, Liu XH, Smaaland R, Cermakian N, Filipski E, Sassone-Corsi P, Lévi F (2005) Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. FASEB J 19:304–306PubMed
23.
24.
Zurück zum Zitat Liu G, Chen X (2006) Regulation of the p53 transcriptional activity. J. Cell. Biochem. 97:448–458CrossRefPubMed Liu G, Chen X (2006) Regulation of the p53 transcriptional activity. J. Cell. Biochem. 97:448–458CrossRefPubMed
25.
26.
Zurück zum Zitat Hu R, Aplin AE (2008) Skp2 regulates G2/M progression in a p53-dependent manner. Mol Biol Cell 19:4602–4610CrossRefPubMed Hu R, Aplin AE (2008) Skp2 regulates G2/M progression in a p53-dependent manner. Mol Biol Cell 19:4602–4610CrossRefPubMed
27.
Zurück zum Zitat Blum-Jensen P, Hunter T (2001) Oncogenic kinase singaling. Nature 411:355–365CrossRef Blum-Jensen P, Hunter T (2001) Oncogenic kinase singaling. Nature 411:355–365CrossRef
28.
Zurück zum Zitat Vira M, Henriksson M (2006) The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biof. 16:318–330CrossRef Vira M, Henriksson M (2006) The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biof. 16:318–330CrossRef
29.
Zurück zum Zitat Wu Ch, Riggelen J, Yetil A (2007) et a1, Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. PNAS. 104:13028–13033CrossRefPubMed Wu Ch, Riggelen J, Yetil A (2007) et a1, Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. PNAS. 104:13028–13033CrossRefPubMed
30.
Zurück zum Zitat Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411:342–348CrossRefPubMed Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411:342–348CrossRefPubMed
Metadaten
Titel
Per2 Inhibits K562 Leukemia Cell Growth In Vitro and In Vivo Through Cell Cycle Arrest and Apoptosis Induction
verfasst von
Cheng-ming Sun
Shi-feng Huang
Jian-ming Zeng
Din-bing Liu
Qing Xiao
Wen-jun Tian
Xi-dan Zhu
Zong-gan Huang
Wen-li Feng
Publikationsdatum
01.09.2010
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 3/2010
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-009-9227-0

Weitere Artikel der Ausgabe 3/2010

Pathology & Oncology Research 3/2010 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.